Catalent

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, SCX, EVBG, NS

Retrieved on: 
Thursday, April 4, 2024
Catalent, Starrett, NuStar Energy, NuSTAR, Sale, Everbridge, Sunoco, Fraud, Thoma Bravo, Advertising, Security (finance)

If you are a Catalent shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Catalent shareholder, click here to learn more about your rights and options .
  • If you are a Starrett shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG

Retrieved on: 
Thursday, April 4, 2024
Empire, NuStar Energy, SCX, Everbridge, Sale, Catalent, CTLT, Thoma Bravo, NS, Security (finance)

Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.

Key Points: 
  • Under the terms of the agreement, NS shareholders are expected to receive 0.4 shares of Sunoco per share they own.
  • Under the terms of the agreement, CTLT shareholders will receive $63.50 in cash per share they own.
  • Under the terms of the agreement, EVBG shareholders will receive $28.60 in cash per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you file class actions and go to Court?

Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm

Retrieved on: 
Friday, March 22, 2024
Catalent, PLLC, Human, General Atlantic, NGM, Column, HireRight, Advertising, Superior, Security (finance)

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.
  • Kuehn Law covers all case costs and does not charge its investor clients.

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Biotechnology, FDA, Health, Pharmaceutical, Optical, Health Technology, Medical Devices, Hospitals, Surgery, Clinical Trials, Catalent, Series, Absorption, Midazolam, Ketamine, Medication

Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.

Key Points: 
  • Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre‑money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019.
  • The capital raised will primarily support the further development of MELT-300, including the MELT-300 Phase 3 program.
  • “With this round of financing, we’ve obtained the funding to further the development of MELT-300, including conducting our recently commenced Phase 3 program.
  • Their shared belief in the vision of MELT-300 and their confidence in its potential to revolutionize short-duration procedural sedation is incredibly valuable to us.”
    Newbridge Securities Corporation acted as the exclusive placement agent for the Series B Preferred Stock Offering.

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Catalent, Plug and play, Patient, Therapy, CDMO, ADC, Engineering, Inc., Pharmaceutical industry

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.

Key Points: 
  • Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions.
  • The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.
  • Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary.
  • Driven by our mission to deliver groundbreaking therapies to patients worldwide and a commitment to innovation and excellence, Invenra is a leading bispecific antibody technology company.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Monday, March 25, 2024
Catalent, Medical device, Temperature, Growth, Prevalence, Face, Molecule, Thermo Fisher Scientific, Medication, CTSL, Pharmacy, Partnership, Intelligence, Imp, Conditional sentence, ICON, Global health, Research, Good manufacturing practice, IMP, Transport, ICON PLC, Placebo, Infosys, GMP, Excipient, Investment, Clinical trial, GDP, Drug development, API, Clinical data management, Table, Ageing, Parexel

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Cellipont Bioservices Appoints Edwin Beale as Chief Commercial Officer

Retrieved on: 
Tuesday, March 12, 2024
Catalent, CDMO, Growth, AstraZeneca, Patient, UNC, Business development, Acquisition, Tuskegee University, Lentivirus, Consultant, Molecular biology, Marketing, UNC Kenan–Flagler Business School

THE WOODLANDS, Texas, March 12, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.

Key Points: 
  • THE WOODLANDS, Texas, March 12, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.
  • Edwin's leadership will be instrumental in further establishing Cellipont as a leading partner for CDMO services in the rapidly growing cell therapy market.
  • In his new role, Mr. Beale will oversee all commercial operations at Cellipont, playing a pivotal role in driving strategic growth and expansion.
  • I look forward to serving our clients and surpassing their expectations," said Edwin Beale, Chief Business Officer.